Editorial Board

• Feb 01, 2026
• Annals of Oncology

Cite

Listen

Save

80eP The correlation of Ki-67 and ER beta as prognostic markers in triple-negative breast cancer

• Dec 01, 2025
• Annals of Oncology
• Y Adinugroho + 1 more +1

Cite

Listen

Save

659eP Comparative outcomes of uterine vs extra-uterine leiomyosarcoma in females: A SEER-based study

• Dec 01, 2025
• Annals of Oncology
• K.i Naser + 1 more +1

Cite

Listen

Save

34P Results of repeat core needle biopsies in ER+/HER2-negative breast cancer following neoadjuvant endocrine therapy with fulvestrant+triptorelin+ribociclib in premenopausal women

• Dec 01, 2025
• Annals of Oncology
• A Vahitova + 7 more +7

Cite

Listen

Save

966eP Investigation of driver gene alterations in stage IV or recurrent non-small cell lung cancer at our institution

• Dec 01, 2025
• Annals of Oncology
• Y Kaburaki + 7 more +7

Cite

Listen

Save

480eTiP YOUNG-NEOS: Phase II study of neoadjuvant nab-paclitaxel, oxaliplatin s-1, and sintilimab for resectable early-onset GC/GEJC patients

• Dec 01, 2025
• Annals of Oncology
• X Zhao + 3 more +3

Cite

Listen

Save

689P NACT with DCF plus low-dose nivolumab in locally advanced technically unresectable oral cavity cancer: A single-centre study from eastern India

• Dec 01, 2025
• Annals of Oncology
• A.a Bhange + 14 more +14

Cite

Listen

Save

346P Adjuvant TACE combined with Tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial

• Dec 01, 2025
• Annals of Oncology
• T Ma + 9 more +9

Cite

Listen

Save

464eP Phase II trial of adjuvant sintilimab in lymph node-positive esophageal squamous cell carcinoma (ESCC) after radical surgery without neoadjuvant treatment

• Dec 01, 2025
• Annals of Oncology
• C Wang + 11 more +11

Cite

Listen

Save

432eP Predictive validity of the ACS NSQIP Risk calculator in patients undergoing surgery for gastrointestinal cancers

• Dec 01, 2025
• Annals of Oncology
• J Yadav + 2 more +2

Cite

Listen

Save